LMNX
$32.52
Luminex
($.47)
(1.42%)
LMNX
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  $0.15
Revenue:  $110.59 Mil
Monday
May 10
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when LMNX reports earnings?
Beat
Meet
Miss

Where is LMNX's stock price going from here?
Up
Flat
Down
Stock chart of LMNX
Analysts
Summary of analysts' recommendations for LMNX
Score
Grade
Pivots
Resistance
$35.34
$34.12
$33.32

$32.10

Support
$31.30
$30.08
$29.28
Tweet
Growth
Description
Luminex Corporation is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.
Peers
IncyteAlexion PharmaceuticalsExact SciencesCharles River Laboratories InternationalExelixisCoherus Biosciences